# Araceli Biosciences Inc.: Form D capital raise (Tigard, OR)

**Vendor Spend Propensity Score (CPA / Tax / Audit):** 77/100
**Estimated post-raise budget for this service type:** $50,521 (heuristic)

| Field | Value |
|---|---|
| Industry | Other Technology (Technology & SaaS) |
| Operating company | Yes |
| Exemption | 506(b) |
| Amount sold | $2,526,065 |
| Total offering | $4,500,000 |
| Investors so far | 4 |
| First sale | 2026-10-20 |
| Filed | 2026-11-03 |
| Entity | Corporation, incorporated 2022 |

## Executives and related persons (as listed in the filing)
- Matt Beaudet: Executive Officer, Director
- Shawn MacDonald: Executive Officer
- William Cortelyou: Director
- J. William Freytag: Director
- Kirk Malloy: Director
- Sean O'Neill: Director
- Samraat Raha: Director
- Bruce Rhine: Director
- Christine Ann Tsingos: Director

## Why this score
- Operating company: new capital typically funds hiring, facilities and vendors.
- Raised $2,526,065 so far.
- Technology & SaaS companies are a strong fit for CPA / Tax / Audit services.
- New filing (not an amendment): the raise is fresh.
- Filed 2 days ago.
- Incorporated in the last five years: likely still building out finance and insurance.

Source: SEC EDGAR Form D filings (U.S. Securities and Exchange Commission) (https://www.sec.gov/Archives/edgar/data/1975014/000197501426000004/). Last refreshed: 2026-11-04T09:16:10.755Z.
Informational only. SEC EDGAR Form D data is shown for business-development research; it is not investment advice and not an offer or solicitation to buy or sell any security. Not legal or financial advice.